

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) An attenuated *Salmonella* strain comprising a eukaryotic expression vector comprising a eukaryotic promoter and a nucleic acid encoding a polypeptide, wherein said nucleic acid is under the control of said eukaryotic promoter, wherein the attenuation is suitable for administration to ~~a vaccination of~~ a vertebrate, and wherein said administration to ~~vaccination of~~ said vertebrate with said attenuated *Salmonella* strain results in expression of said polypeptide by said vertebrate and generates ~~an immune a~~ response by said vertebrate to said polypeptide.
2. (previously presented) The *Salmonella* strain of claim 1, wherein the strain is a *S. typhimurium* strain.
3. (previously presented) The *Salmonella* strain of claim 2, wherein the strain is selected from the group consisting of *S. typhimurium* aroA SL 7207, *S. typhimurium* LT2, and *S. typhimurium* aroA544 (ATCC Accession No. 33275).
4. (previously presented) The *Salmonella* strain of claim 1, wherein the strain is a *S. typhi* strain.
5. (previously presented) The *Salmonella* strain of claim 4, wherein the strain is *S. typhi* Ty21a.
6. (previously presented) The *Salmonella* strain of claim 1, wherein the eukaryotic expression vector is derived from plasmid pCMV $\beta$ , wherein the plasmid comprises:
  - a) a structural gene of  $\beta$ -galactosidase ( $\beta$ -gal) under the control of a human cytomegalovirus (CMV) immediate early promoter,
  - b) a splice donor,
  - c) two splice acceptor sites between the promoter and the  $\beta$ -galactosidase gene, and
  - d) a polyadenylation site of SV40.

7-8. (canceled)

9. (previously presented) The *Salmonella* strain of claim 1, wherein the polypeptide is selected from the group consisting of an *Escherichia coli*- $\beta$ -galactosidase, a non-hemolytic truncated *Listeria monocytogenes*-listeriolysin, and a truncated *Listeria monocytogenes*-actA polypeptide.

10. (previously presented) A vaccine comprising the *Salmonella* strain of claim 1.

11-16. (canceled)

17. (previously presented) The *Salmonella* strain of claim 1, wherein the encoded polypeptide is capable of inducing an antibody response and a T-cell response, wherein the T-cell response comprises production of CD8 T-cells and CD4 T-cells.

18. (previously presented) The *Salmonella* strain of claim 1, wherein the encoded polypeptide is capable of inducing an antibody response and a T-cell response, wherein the antibody response comprises production of IgG1, IgG2, and IgA antibodies.

19. (previously presented) The *Salmonella* strain of claim 1, wherein the vertebrates are humans.

20. (previously presented) The *Salmonella* strain of claim 1, wherein *Salmonella* is orally administered.

21. (previously presented) The *Salmonella* strain of claim 18, wherein the antibody response is induced after a single immunization.

22. (previously presented) The *Salmonella* strain of claim 17, wherein the T-cell response is induced after a single immunization.

23. (previously presented) The *Salmonella* strain of claim 9, wherein the polypeptide is a non-hemolytic truncated *Listeria monocytogenes*-listeriolysin polypeptide.